ATE374039T1 - Tnf-peptide und deren verwendung zur behandlung von ödemen - Google Patents
Tnf-peptide und deren verwendung zur behandlung von ödemenInfo
- Publication number
- ATE374039T1 ATE374039T1 AT02077256T AT02077256T ATE374039T1 AT E374039 T1 ATE374039 T1 AT E374039T1 AT 02077256 T AT02077256 T AT 02077256T AT 02077256 T AT02077256 T AT 02077256T AT E374039 T1 ATE374039 T1 AT E374039T1
- Authority
- AT
- Austria
- Prior art keywords
- alpha
- present
- oedema
- edema
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98870180 | 1998-08-14 | ||
| EP98870198 | 1998-09-18 | ||
| EP98870222 | 1998-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE374039T1 true ATE374039T1 (de) | 2007-10-15 |
Family
ID=27239778
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02077256T ATE374039T1 (de) | 1998-08-14 | 1999-08-10 | Tnf-peptide und deren verwendung zur behandlung von ödemen |
| AT02077274T ATE395072T1 (de) | 1998-08-14 | 1999-08-10 | Tnf-peptide zur behandlung von ödemen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02077274T ATE395072T1 (de) | 1998-08-14 | 1999-08-10 | Tnf-peptide zur behandlung von ödemen |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20030105021A1 (https=) |
| EP (3) | EP1264599B1 (https=) |
| JP (1) | JP4542266B2 (https=) |
| CN (1) | CN1181886C (https=) |
| AT (2) | ATE374039T1 (https=) |
| AU (1) | AU764992B2 (https=) |
| BR (1) | BR9912899A (https=) |
| CA (1) | CA2334941C (https=) |
| CZ (1) | CZ302862B6 (https=) |
| DE (2) | DE69938743D1 (https=) |
| DK (1) | DK1264599T3 (https=) |
| ES (1) | ES2296872T3 (https=) |
| HU (1) | HU227661B1 (https=) |
| IL (2) | IL141064A0 (https=) |
| NZ (1) | NZ509604A (https=) |
| PL (1) | PL203706B1 (https=) |
| PT (1) | PT1264599E (https=) |
| TR (1) | TR200100338T2 (https=) |
| WO (1) | WO2000009149A1 (https=) |
| ZA (1) | ZA200100656B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1264599B1 (en) | 1998-08-14 | 2007-09-26 | Rudolf Lucas | TNF-derived peptides for use in treating oedema |
| CA2575513C (en) * | 2004-08-06 | 2014-09-16 | Altana Pharma Ag | Composition comprising a pulmonary surfactant and a tnf-derived peptide |
| EP2009023A1 (en) * | 2007-06-04 | 2008-12-31 | Rentschler Beteiligungs GmbH | Novel peptides and their use for the treatment of edema |
| AT506151B1 (de) | 2007-12-12 | 2010-01-15 | Apeptico Forschung Und Entwick | Fusionsprotein |
| AT506150B1 (de) * | 2007-12-12 | 2010-01-15 | Apeptico Forschung Und Entwick | Zyklisches und cystein-freies peptid |
| AT507953B1 (de) | 2009-03-05 | 2011-02-15 | Apeptico Forschung & Entwicklung Gmbh | Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität |
| AT509267A1 (de) * | 2010-01-14 | 2011-07-15 | Apeptico Forschung & Entwicklung Gmbh | Organische verbindungen zur regulierung von vektoriellen ionenkanälen |
| PL2397151T3 (pl) * | 2010-06-21 | 2015-10-30 | Apeptico Forschung & Entwicklung Gmbh | Leczenie powikłań naczyniowych cukrzycy |
| US11161881B2 (en) * | 2010-11-18 | 2021-11-02 | Apeptico Forschung Und Entwicklung Gmbh | Composition comprising a peptide and an inhibitor of viral neuraminidase |
| AT510585B1 (de) | 2010-11-18 | 2012-05-15 | Apeptico Forschung & Entwicklung Gmbh | Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase |
| EP2679239A1 (de) * | 2012-06-28 | 2014-01-01 | Apeptico Forschung und Entwicklung GmbH | Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit |
| US12004506B2 (en) | 2013-04-23 | 2024-06-11 | Apeptico Forschung Und Entwicklung Gmbh | Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment |
| US20160143266A1 (en) * | 2013-04-23 | 2016-05-26 | Apeptico Forschung Und Entwicklung Gmbh | Pharmaceutical Composition Comprising a Cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment |
| US10925924B2 (en) | 2014-03-18 | 2021-02-23 | Apeptico Forschung Und Entwicklung Gmbh | Dry-powder peptide medicament |
| CN110613838A (zh) * | 2018-06-19 | 2019-12-27 | 姜石松 | 增强细胞通透性的多肽及其应用 |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| CN115461356A (zh) | 2020-05-08 | 2022-12-09 | 阿佩普蒂科研究和开发有限责任公司 | 用于预防或治疗covid-19的肽 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE384179C (de) * | 1921-04-07 | 1923-10-27 | Ludwig Weil Dr | Laufrad fuer Kreiselpumpen und -geblaese |
| DE3841759A1 (de) * | 1988-12-12 | 1990-06-13 | Basf Ag | Neue tnf-peptide |
| WO1994018325A1 (en) * | 1993-02-03 | 1994-08-18 | N.V. Innogenetics S.A. | Tnf-alpha muteins and a process for preparing them |
| EP1264599B1 (en) | 1998-08-14 | 2007-09-26 | Rudolf Lucas | TNF-derived peptides for use in treating oedema |
-
1999
- 1999-08-10 EP EP02077256A patent/EP1264599B1/en not_active Expired - Lifetime
- 1999-08-10 AT AT02077256T patent/ATE374039T1/de active
- 1999-08-10 NZ NZ509604A patent/NZ509604A/en not_active IP Right Cessation
- 1999-08-10 DE DE69938743T patent/DE69938743D1/de not_active Expired - Lifetime
- 1999-08-10 HU HU0103117A patent/HU227661B1/hu not_active IP Right Cessation
- 1999-08-10 EP EP02077274A patent/EP1247531B1/en not_active Expired - Lifetime
- 1999-08-10 EP EP99942835A patent/EP1105152A1/en not_active Withdrawn
- 1999-08-10 CA CA2334941A patent/CA2334941C/en not_active Expired - Lifetime
- 1999-08-10 JP JP2000564651A patent/JP4542266B2/ja not_active Expired - Lifetime
- 1999-08-10 DE DE69937206T patent/DE69937206T2/de not_active Expired - Lifetime
- 1999-08-10 AU AU56209/99A patent/AU764992B2/en not_active Ceased
- 1999-08-10 DK DK02077256T patent/DK1264599T3/da active
- 1999-08-10 ES ES02077256T patent/ES2296872T3/es not_active Expired - Lifetime
- 1999-08-10 AT AT02077274T patent/ATE395072T1/de active
- 1999-08-10 PL PL345997A patent/PL203706B1/pl unknown
- 1999-08-10 PT PT02077256T patent/PT1264599E/pt unknown
- 1999-08-10 WO PCT/EP1999/005806 patent/WO2000009149A1/en not_active Ceased
- 1999-08-10 CN CNB998096555A patent/CN1181886C/zh not_active Expired - Lifetime
- 1999-08-10 CZ CZ20010538A patent/CZ302862B6/cs not_active IP Right Cessation
- 1999-08-10 BR BR9912899-3A patent/BR9912899A/pt active Search and Examination
- 1999-08-10 IL IL14106499A patent/IL141064A0/xx unknown
- 1999-08-10 TR TR2001/00338T patent/TR200100338T2/xx unknown
-
2001
- 2001-01-23 ZA ZA2001/00656A patent/ZA200100656B/en unknown
- 2001-01-24 IL IL141064A patent/IL141064A/en not_active IP Right Cessation
- 2001-02-09 US US09/779,703 patent/US20030105021A1/en not_active Abandoned
-
2002
- 2002-06-06 US US10/162,553 patent/US7258861B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE374039T1 (de) | Tnf-peptide und deren verwendung zur behandlung von ödemen | |
| EA200400632A1 (ru) | Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток | |
| ATE285224T1 (de) | Methode zur prävention und behandlung von dehnungsstreifen (striae distensae) und deren verwendung in dermatologie | |
| DE69904511D1 (de) | Proteinmaterial mit verlangsamtem verdaungsablauf und deren verwendung | |
| DE69906671D1 (de) | Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen | |
| ATE233558T1 (de) | Verwendung von strontiumsälze zur behandlung von arthrose | |
| ATE326239T1 (de) | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren | |
| CY1111120T1 (el) | Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση | |
| EA200000652A1 (ru) | Кристаллы глюкагоноподобного пептида 1 | |
| EA200400205A1 (ru) | Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток | |
| DE60331546D1 (de) | Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung | |
| ATE377026T1 (de) | Behandlung von fettleibigkeit | |
| AR002742A1 (es) | Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn | |
| ATE118009T1 (de) | Substituierte alpha-aminosäuren mit pharmazeutischer aktivität. | |
| DE69329899D1 (de) | Behandlung von tropikalischer spastischer Paresis mit Peptide T | |
| DE602004016834D1 (de) | Zusammensetzung zur vermeidung und behandlung von cellulitis | |
| DE69904010D1 (de) | Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren | |
| DE69526972D1 (de) | Verwendung von Gabapentin in der Behandlung vonAngst - und Panikstörungen | |
| ATE336992T1 (de) | Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz- erkrankungen | |
| DE3786456D1 (de) | Kombinationen von nekrose-tumor-faktoren und entzuendungshemmenden mitteln fuer die behandlung von boesartigen und nicht boesartigen erkrankungen. | |
| DE69503724D1 (de) | L-Carnitin-Salz, dieses enthaltende kosmetische und pharmazeutische Zusammensetzungen zur Behandlung von Dermatosen | |
| ATE342352T1 (de) | Entwurf und verwendung von verbesserten zink- chelatbildenden peptiden zur regulation von matrix-metalloproteinasen | |
| ATE181240T1 (de) | Verwendung von somatostatinanalogen zur behandlung von melanomen | |
| DE50001730D1 (de) | Gemisch zur behandlung von abfallmaterial | |
| DE69224750D1 (de) | Peptide und Antikörper zur Behandlung von rheumatoider Arthritis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1264599 Country of ref document: EP |
|
| EEIH | Change in the person of patent owner |